Citation Impact
Citing Papers
Generation of knock-in primary human T cells using Cas9 ribonucleoproteins
2015 StandoutNobel
Identification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia
2017
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
2016
A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
2021 StandoutScienceNobel
The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins
2019 StandoutNobel
A sex-biased imbalance between Tfr, Tph, and atypical B cells determines antibody responses in COVID-19 patients
2023 StandoutNobel
Mouse models of acute and chronic hepacivirus infection
2017 StandoutScienceNobel
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
2015
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
2017
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Cancer statistics, 2020
2020 Standout
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy
2017
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
2016
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
2015
A view on drug resistance in cancer
2019 StandoutNature
Combination cancer immunotherapy and new immunomodulatory targets
2015
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
2016
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes
2015
The biology and management of non-small cell lung cancer
2018 StandoutNature
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
2017 StandoutNobel
Angiogenesis and antiangiogenic therapy in hematologic malignancies
2006
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
2018 StandoutNobel
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
2017 Standout
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
2015
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
2018
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
2018
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Overcoming T cell exhaustion in infection and cancer
2015
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
2015
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Emerging Biological Principles of Metastasis
2017 Standout
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
2016 Standout
Antagonists of PD-1 and PD-L1 in Cancer Treatment
2015
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
2016
Functional evaluation before lung resection
2002
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
2016
PD-1/PD-L1 inhibitors
2015
Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy
2018 StandoutNobel
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
2017
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
2016
Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
2017
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
2016
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Gene-expression profiling to predict responsiveness to immunotherapy
2016
The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma
2016
Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging
2019
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
2017
T cell metabolic fitness in antitumor immunity
2015
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
2018
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
2016 StandoutNobel
Innate immune signaling and regulation in cancer immunotherapy
2016
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
2015 Standout
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Tumor Angiogenesis
2008 Standout
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2012 Standout
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Roles of regulatory T cells in cancer immunity
2016
Managing Immune Checkpoint-Blocking Antibody Side Effects
2015
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
2016
Lysosomal cathepsin D mediates endogenous mucin glycodomain catabolism in mammals
2022 StandoutNobel
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
Spermidine in health and disease
2018 StandoutScience
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
2018 StandoutScience
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Toxicities of Immunotherapy for the Practitioner
2015
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting
2016
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
2018
The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis
2016
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors
2016
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
2015
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma
2017
Neoantigens in cancer immunotherapy
2015 StandoutScience
Adaptive Immune Resistance: How Cancer Protects from Immune Attack
2015
CRISPR-Cas guides the future of genetic engineering
2018 StandoutScienceNobel
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
N‐Carboxyanhydride Polymerization of Glycopolypeptides That Activate Antigen‐Presenting Cells through Dectin‐1 and Dectin‐2
2018 StandoutNobel
Immune checkpoint inhibitors in challenging populations
2017
Works of Michael Millenson being referenced
Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung
2000
Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.
2004
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout